BioProject

Purpose: Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. More...

Purpose: Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. The goal of this work is to explore how the histone methyltransferase EZH2 interacts with ER signaling and drives the insensitiveness of breast cancer cells to the antagonistic effect of tamoxifen on ER activity. Therefore, we comprehensively analyzed the transcriptional program regulated by EZH2 in EZH2 overexpressed MCF-7 cells. Methods: MCF-7 cells between passage 142-144 were used for this assay. For mRNA-Seq, cells are infected with control empty vector (EV) or EZH2 expressing plasmid (EZH2) by lentivirus. Total RNA were extracted by TRIzol (Invitrogen) and libraries were constructed using Illumina TruSeq RNA Sample Prep Kit v2 (Cat.# RS-122-2001). Hiseq 3000 was used for sequencing. Overall design: Transcriptome profiles of tamoxifen sensitive MCF-7 infected with pLenti-CMV-hygro-GFP or pLento-HA-EZH2 were sequenced in at least duplicates using Illumina HiSeq 3000. Less...